SRZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Surrozen Inc (SRZN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock shows positive insider buying trends, bullish technical indicators, and strong analyst ratings with significant upside potential. Despite a drop in revenue, the company's financials show improvement in net income and EPS, and its pipeline addresses a large market opportunity in retinal diseases.
The technical indicators for SRZN are bullish. The MACD histogram is positive and contracting, suggesting potential upward momentum. The RSI is neutral at 49.708, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 30.514, R1: 33.364, S1: 27.664, R2: 35.124, S2: 25.904.
Insider buying has increased significantly by 661.32% over the last month.
Analysts are highly optimistic about the company's potential in addressing a $5B+ market opportunity in retinal diseases.
Strong bullish technical indicators and a high probability of short-term price gains (6.96% in the next week, 21.05% in the next month).
Revenue dropped by 19.39% YoY in the latest quarter.
No recent news or significant hedge fund activity.
In 2025/Q4, the company's revenue dropped to $528,000 (-19.39% YoY). However, net income improved significantly to -$183.16M (+553.23% YoY), and EPS increased to -20.09 (+133.06% YoY). Gross margin remained stable at 100%.
Analysts are optimistic about SRZN. TD Cowen initiated coverage with a Buy rating, citing a $5B+ market opportunity. H.C. Wainwright raised the price target to $36 from $32 and maintained a Buy rating. Cantor Fitzgerald initiated coverage with an Overweight rating and a $40 price target, highlighting the company's leadership in Wnt biology and its potential in retinal diseases.
